Sofinnova leads €22m series-A for Enyo Pharma
Life sciences investor Sofinnova Partners, the backer of a seed round for French biotech Enyo Pharma in 2015, has led a €22m series-A for the business alongside Morningside Ventures and BPI France.
According to an unquote" source, Sofinnova drew equity from its €240m seventh fund. The deal is the last to be financed via the vehicle, this same source added; Sofinnova's future investments will come from its eighth fund, which closed on €300m in December 2015.
Meanwhile, BPI France provided €5m of the total €22m ticket.The state investor used its InnoBio fund, a healthcare-focused €173m FCPI fund launched alongside big pharma names including Roche and Novartis in November 2009; Enyo represents the vehicle's 18th investment.
Over the next few months, Enyo will use the capital to finance the launch of phase-1 clinical trials for its core product, a compound used to treat hepatitis B. In addition, the biotech intends to set up a separate scheme dedicated to influenza treatment.
The round comes a year after Enyo received €1m in seed capital from Sofinnova. The VC was previously acquainted with the biotech's CEO Jacky Vonderscher; the executive sits on the board of Sofinnova's Swiss portfolio company ObsEva, which was backed via a CHF 32m series-A in 2013 and a CHF 60m series-B in 2015.
The deal is the second to involve Sofinnova in the space of a few days. Earlier on in the week, the life sciences investor took part in a £60m round for its British portfolio company Mission Therapeutics, led by Woodford Patient Capital Trust.
Company
Founded by Inserm scientists Patrice André and Vincent Lotteau in 2014, Enyo develops therapies against hepatitis B, among other acute and chronic viral infections. Unlike other existing treatments, the biotech's antivirals focus on the patient's cellular functions to prevent the virus from triggering. The company is headquartered at the Infectiology Center of Lyonbiopôle in Lyon.
People
Sofinnova Partners – Rafaèle Tordjman (managing partner).
BPI France – Chahra Louafi (senior investment director); Benoît Barteau (investment manager).
Enyo Pharma – Jacky Vonderscher (CEO).
Advisers
Equity – Dechert, Anne-Charlotte Rivière, Quentin Durand (Legal); Colombus, Gad Aiach (Financial due diligence).
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater